Clinical Trial Update: Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the optimal timing of initiating dronedarone after conversion in patients with persistent atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Dronedarone (dronedarone)

Snippet

Sponsor: Sanofi | Conditions: Atrial Fibrillation | Phase 4 | Status: COMPLETED